Analyst Ranking
Top 24%
#1200 out of 5157 analysts
Average Return
+7.4%
Win Rate
47%24 out of 51
Risk vs Reward
Poor
Good

Uy Ear's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Arcutis Biotherapeutics IncARQT
+306.12%$3.43$13.93
2024-01-02 -
2024-12-31
Strong Buy
Arcutis Biotherapeutics IncARQT
+272.38%$3.91$14.56
2024-01-03 -
2025-01-02
Strong Buy
Mbx Biosciences IncMBX
+154.56%$11.95$30.42
2025-08-05 -
2025-12-19
Buy
Cabaletta Bio IncCABA
+131.36%$8.10$18.74
2023-03-17 -
2024-03-15
Strong Buy
Arcutis Biotherapeutics IncARQT
+111.88%$13.22$28.01
2025-02-26 -
2025-12-19
Buy

Uy Ear Analyst Color

Get additional color on Uy Ear's coverage of popular stocks

Uy Ear's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Neurocrine Biosciences IncNBIX
10Hold$175.00+20.69%Maintains
10 days ago
Uniqure NvQURE
6Buy$33.00+37.56%Maintains
13 days ago
Evolus IncEOLS
4Buy$19.00+168.74%Maintains
20 days ago
Acadia Pharmaceuticals IncACAD
15Hold$29.00+6.77%Maintains
20 days ago
Arcutis Biotherapeutics IncARQT
14Buy$37.00+32.10%Maintains
24 days ago
Relmada Therapeutics IncRLMD
2Buy$10.00+129.89%Upgrades
a month ago
Sarepta Therapeutics IncSRPT
8Buy$26.00+23.57%Upgrades
2 months ago
Alkermes PLCALKS
6Buy$45.00+58.17%Maintains
2 months ago
Mbx Biosciences IncMBX
2Buy$56.00+84.09%Maintains
3 months ago
Tectonic Therapeutic IncTECX
6Buy$85.00+334.56%Maintains
7 months ago
Sage Therapeutics IncSAGE
2Hold$16.00N/AMaintains
a year ago
Cartesian Therapeutics IncRNAC
3Strong Buy$40.00N/AInitiates Coverage On
2 years ago
Revance Therapeutics IncRVNC
1Strong Buy$16.00N/AMaintains
2 years ago
Johnson & JohnsonJNJ
1Strong Buy$40.00N/AMaintains
3 years ago
Satsuma Pharmaceuticals IncSTSA
1Hold$2.00N/AReiterates
3 years ago
Cabaletta Bio IncCABA
1Strong Buy$10.00N/AReiterates
3 years ago
Ocugen IncOCGN
2Strong Buy$3.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.